DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up [Yahoo! Finance]
Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program
Denali Therapeutics Inc. (NASDAQ: DNLI) had its price target lowered by analysts at Bank of America Co. from $30.00 to $28.00. They now have a "buy" rating on the stock.
Denali Therapeutics Inc. (NASDAQ: DNLI) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $33.00 price target on the stock.
Denali Therapeutics Inc. (NASDAQ: DNLI) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $35.00 price target on the stock, down previously from $38.00.